Eton Pharmaceuticals, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Financial statements are unaudited; dollar amounts below are in millions unless stated otherwise.
Business context
Eton develops, acquires and commercializes prescription products for rare diseases. It reported three commercial rare-disease products—ALKINDI SPRINKLE, Carglumic Acid and Betaine Anhydrous—and four additional candidates in late-stage development. It also may receive royalties or milestone payments from products developed and out-licensed.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $5.304 | $2.176 |
| Gross profit / gross margin | $3.346 / 63.1% | $1.327 / 61.0% |
| Research and development | $0.535 | $1.618 |
| General and administrative | $5.345 | $4.796 |
| Operating loss | $(2.534) | $(5.087) |
| Net loss / loss per share | $(2.660) / $(0.10) | $(5.330) / $(0.21) |
| Operating cash flow | $(1.548) | $1.223 |
At March 31, 2023, cash and cash equivalents were $14.708, working capital was approximately $11.6, and total assets were $23.928. Total liabilities were $12.687. Debt was reported at $6.446 net of discount, including $1.339 current and $5.107 long-term; gross loan payable was $6.615. Cash declined $1.597 during the quarter, ending at $14.708. No income tax expense was recorded.
Changes versus the prior comparable period
- Revenue increased 144%, primarily from higher ALKINDI SPRINKLE and Carglumic Acid sales. Gross profit rose $2.019 million and gross margin improved by about 2.1 percentage points.
- Operating loss narrowed by $2.553 million. R&D expense fell $1.083 million, mainly because Q1 2022 included a $0.5 million ZENEO agreement fee and development costs were lower. G&A increased $0.549 million, mainly from sales-force expansion.
- Operating cash flow shifted from $1.223 million provided to $1.548 million used. The prior-year period included a $5 million Azurity milestone receipt; Q1 2023 also had a $1.022 million increase in accounts receivable.
- Cash fell from $16.305 million at year-end 2022 to $14.708 million at March 31, 2023. Shares outstanding increased from 25.353 million to 25.504 million during the quarter.
Outlook, risks and notable items
- Management said cash, approved-product revenues and expected 2023 milestone payments were expected to fund operating and capital needs for at least 12 months from the filing date. This is based on current sales and spending assumptions; the company cautioned that it could use cash sooner and might need additional financing, with no assurance financing would be available on acceptable terms.
- SWK debt principal payments were deferred until May 2023 under an amendment; the remaining principal balance is due in November 2024. The loan is secured by company assets, includes covenants, and the company was discussing an alternative reference rate as LIBOR was being phased out.
- Revenue and receivables were highly concentrated: AnovoRx accounted for 96.3% of Q1 2023 revenue and 95.1% of net receivables at March 31. The company also relies on a small number of third-party suppliers, creating potential interruption risk.
- Bausch Health discontinued sales of Alaway Preservative Free effective March 24, 2023; Eton’s potential royalties on that product may therefore be affected. The filing does not quantify the expected financial impact.
- Eton acquired ET-600 in March 2023, with specified development and commercial milestone payments and tiered royalties. No formal revenue or earnings guidance was provided.
- The company reported no pending or threatened litigation expected to have a material impact, and said disclosure controls and procedures were effective. It reported no material change in internal control over financial reporting.
Investor verification points
- Track whether ALKINDI SPRINKLE and Carglumic Acid sales growth continues and whether the product mix sustains gross margin improvement.
- Monitor customer concentration, receivable collection and cash conversion, given the Q1 operating cash outflow.
- Compare actual cash use and milestone receipts with management’s stated 12-month liquidity expectation.
- Verify SWK principal payments beginning in May 2023, debt covenants, the reference-rate transition and the November 2024 maturity.
- Assess the effect of Alaway Preservative Free sales discontinuation and progress, costs and contingent payments for ET-600 and other candidates.